>>I was told that [manufacturing] will not be a problem and I see nothing other then the fact that they will not disclose specific about production of squalamine to make me think this will be an issue.<<
I’ve spoken with a PhD scientist who worked at GENR for several years and insists that manufacturing is a very big problem indeed. Sour grapes, perhaps, but I’m not inclined to entirely discount such a strong-willed sentiment from an ex-employee.
>>Systemic is an issue as is safety of all drugs until proven otherwise, but 2010? <<
Included in my estimated 67% probability of no Squalamine approval before 2010 is the case where Squalamine is not approved ever.
p.s. It looks like you sold your GTCB too soon. Are you thinking of buying it back?
Market Data 
Markets 
AI
